Agilent IQFISH Lung Cancer Panel

Agilent Technologies has launched its IQFISH lung cancer panel for automated analysis on Dako Omnis in Europe with a CE-IVD mark. The panel comprises ALK, ROS1, RET, and MET IQFISH probes, andwas designed using oligonucleotide-based SureFISH technology with formamide-free IQFISH fast hybridization buffer. The panel allows labs to simultaneously stain IHC and FISH slides and enable multiple FISH slides to be processed in just four hours, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.